Efficacy and safety of RApid PrednIsolone Dose reduction for acute exacerbation of Idiopathic Pulmonary Fibrosis (RAPID-IPF Trial): a study protocol for a randomised controlled trial Authors: Keisuke Anan, Yuki Kataoka, Masataka Taguri, Kazuya Ichikado, Ryo Tachikawa, Kazunori Tobino, Kodai Kawamura, Chigusa Shirakawa, Takafumi Kawabata, Yosuke Yamamoto Published: 2026 ABSTRACT AbstractIntroductionAcute exacerbation of idiopathic pulmonary fibrosis (AE-IPF) is a life-threatening event with high mortality. While systemic corticosteroids are commonly used in clinical practice for AE-IPF despite the absence of randomised evidence, the optimal tapering strategy is uncertain. Early corticosteroid tapering reduces adverse events in other inflammatory diseases. However, the efficacy and safety of this approach in AE-IPF have not been established. This study aims to determine if an early corticosteroid tapering regimen is non-inferior to a conventional regimen for 90-day mortality in patients with AE-IPF.Methods and analysisThe RApid PrednIsolone Dose reduction for acute exacerbation of Idiopathic Pulmonary Fibrosis (RAPID-IPF) trial is a multicentre, parallel-group, open-label, randomised controlled non-inferiority trial conducted in Japan. A total of 70 patients (up to 130) hospitalised for AE-IPF will be randomly assigned in a 1:1 ratio to either an accelerated 6-week prednisolone tapering regimen (early tapering group) or a conventional 12-week tapering regimen (standard tapering group). The primary outcome is all-cause mortality at 90 days. The non-inferiority margin is set at a 10% risk difference. Key secondary outcomes include 28-day mortality, mortality due to respiratory causes, time to respiratory worsening or death, protocol adherence and the proportion of patients lost to follow-up. The trial incorporates two interim analyses for feasibility and sample size re-estimation.Ethics and disseminationThis study will be conducted in compliance with the Declaration of Helsinki and Japanese ethical guidelines. The protocol was approved by the institutional review boards of all participating hospitals (lead approval: Saiseikai Kumamoto Hospital, #1367). Written informed consent will be obtained from all participants or their legally acceptable representatives. Findings will be disseminated through scientific conferences and publication in a peer-reviewed journal.Trial registration numberJapan Registry of Clinical Trials (jRCT1071250015).Keywords: Idiopathic Pulmonary Fibrosis WHAT IS ALREADY KNOWN ON THIS TOPIC Systemic corticosteroids are commonly used in clinical practice for acute exacerbations of idiopathic pulmonary fibrosis (AE-IPF) despite the absence of high-quality randomised evidence, but the optimal tapering strategy is unknown. Systemic corticosteroids are commonly used in clinical practice for acute exacerbations of idiopathic pulmonary fibrosis (AE-IPF) despite the absence of high-quality randomised evidence, but the optimal tapering strategy is unknown. Prolonged high-dose corticosteroid therapy increases the risk of serious adverse events, and evidence for a safer, effective tapering regimen is urgently needed. Prolonged high-dose corticosteroid therapy increases the risk of serious adverse events, and evidence for a safer, effective tapering regimen is urgently needed. WHAT THIS STUDY ADDS This protocol describes the first prospective, randomised controlled trial to investigate whether an accelerated 6-week corticosteroid tapering regimen is non-inferior to a conventional 12-week regimen in terms of 90-day mortality for patients with AE-IPF. This protocol describes the first prospective, randomised controlled trial to investigate whether an accelerated 6-week corticosteroid tapering regimen is non-inferior to a conventional 12-week regimen in terms of 90-day mortality for patients with AE-IPF. HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY If non-inferiority is suggested, this study could provide important preliminary evidence to inform clinical practice and the design of future confirmatory trials, while potentially supporting future guideline development. If non-inferiority is suggested, this study could provide important preliminary evidence to inform clinical practice and the design of future confirmatory trials, while potentially supporting future guideline development. Introduction Idiopathic pulmonary fibrosis (IPF) is a progressive fibrosing lung disease with a poor prognosis.1 An estimated 5%–15% of patients with IPF experience an acute exacerbation (AE-IPF) within 1 year,2 a life-threatening event with an in-hospital mortality that often exceeds 50%.3 4 Despite the availability of several therapeutic options for AE-IPF, none have been definitively proven effective in clinical trials, highlighting an urgent need for a validated treatment strategy.5 6 Systemic corticosteroids represent the most frequently employed therapeutic strategy for AE-IPF. While their efficacy has not been confirmed in randomised controlled trials (RCTs), international guidelines provide a conditional recommendation for their use,7 and they are commonly used in clinical practice. A common approach to administration involves an initial high-dose treatment, followed by a gradual dose reduction over several weeks or months.5 Despite this widespread acceptance, a significant gap in knowledge exists regarding the optimal corticosteroid administration strategy. Specifically, there is no established consensus on the tapering regimen for patients with AE-IPF, and prominent international guidelines do not provide specific recommendations on the method or duration of dose reduction.7 This lack of guidance creates a clinical challenge, as prolonged high-dose therapy increases the risk of serious adverse events (SAEs). While early tapering has proven beneficial in other inflammatory conditions by mitigating steroid-related toxicity without compromising outcomes,8 9 its efficacy and safety in the context of AE-IPF remain uninvestigated. Although our previous retrospective cohort study suggested a potential survival benefit with an early tapering approach,10 the limitations of observational data, such as confounding by indication and variability in treatment regimens, necessitate validation with a prospective, RCT. This study, the RApid PrednIsolone Dose reduction for acute exacerbation of Idiopathic Pulmonary Fibrosis (RAPID-IPF) trial, aims to assess whether a rapid (6 weeks) prednisolone tapering regimen is non-inferior to a conventional (12 weeks) tapering regimen in terms of 90-day all-cause mortality in patients with AE-IPF. We hypothesise that the early tapering regimen will be non-inferior to the conventional regimen for 90-day mortality, while potentially reducing cumulative steroid exposure and related adverse events. Methods This manuscript constitutes the full study protocol (version 1.2, dated 31 July 2025). We reported this protocol in accordance with the updated guidelines for protocols of randomised trials (The Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) 2025 statement)11 (online supplemental table S1). Trial registration This trial was registered with the Japan Registry of Clinical Trials (jRCT) on 2 May 2025. The registration number is jRCT1071250015. The full trial registration data can be accessed online (https://jrct.mhlw.go.jp/re/reports/detail/94178). Protocol and statistical analysis plan This manuscript constitutes the full study protocol. A separate, detailed Statistical Analysis Plan (SAP) will be finalised before database lock and the start of the final analysis. The SAP will be made available on reasonable request to the corresponding author after the publication of the primary trial results. There are no plans to make the SAP publicly available prior to trial completion. Trial design The RAPID-IPF trial is a multi-centre, parallel-group, active-controlled, open-label, RCT designed to assess the non-inferiority of a rapid (6 weeks) prednisolone tapering regimen compared with a conventional (12 weeks) tapering regimen in patients with AE-IPF. The 12-week conventional tapering regimen was chosen as the comparator. This duration reflects current clinical practice, as a large international survey reported that the average duration of corticosteroid treatment for AE-IPF was 13 weeks.5 Based on this evidence and expert consensus within the study group, a 12-week regimen was established as a representative conventional treatment strategy. Eligible patients will be randomly allocated in a 1:1 ratio to either the rapid tapering group or the standard tapering group. The primary framework of the trial is non-inferiority, aiming to demonstrate that the 90-day all-cause mortality in the rapid tapering group is not unacceptably worse than that in the standard tapering group, with a prespecified non-inferiority margin of 10% for the risk difference. In the context of AE-IPF, where placebo-controlled trials are lacking to establish the effect of current empirical therapy, defining this margin is particularly challenging. Our margin of 10 percentage points was established through a consensus-based approach informed by data from a large international survey suggesting a high mortality even with current empirical clinical practice5 and was determined by expert consensus among the investigators. This margin is further supported by evidence from the literature demonstrating that a 10% non-inferiority margin for mortality outcomes falls within the range used in trials involving other high-mortality conditions.12,15 It balances the substantial potential benefits of the early tapering regimen—namely, a considerable reduction in cumulative steroid exposure and associated adverse events—against a modest and clinically acceptable degree of uncertainty regarding mortality. The trial incorporates a two-stage design: an initial stage to assess feasibility, followed by the main non-inferiority comparison. Trial setting This is a multicentre trial that will be conducted in tertiary care hospitals across Japan. Initially, patients will be recruited from Saiseikai Kumamoto Hospital, Kobe City Medical Center General Hospital and Iizuka Hospital. Additional participating sites, which will be tertiary care hospitals or specialised respiratory centres, will be added during the trial if interim analyses indicate that the trial is feasible to continue and expand, or if patient recruitment is slower than anticipated, to ensure an adequate sample size. Inclusion and exclusion criteria In brief, this trial will enrol patients aged 40 years or older who are hospitalised for an AE-IPF and have initiated corticosteroid pulse therapy. Key exclusion criteria include exacerbations primarily due to other causes (eg, infection or heart failure), coexisting active malignancy and current mechanical ventilation. The detailed inclusion and exclusion criteria for participant enrolment are listed in box 1. Eligibility criteria Inclusion criteria Patients must meet all of the following criteria to be eligible for enrolment: Aged 40 years or older. Aged 40 years or older. Diagnosis of IPF or IPF (likely) according to the ATS/ERS/JRS/ALAT 2022 international guidelines.1 Diagnosis of IPF or IPF (likely) according to the ATS/ERS/JRS/ALAT 2022 international guidelines.1 Diagnosis of AE-IPF based on the 2016 international working group criteria.2 Diagnosis of AE-IPF based on the 2016 international working group criteria.2 Able to provide written informed consent, either by the patient themselves or by a legally acceptable representative. Able to provide written informed consent, either by the patient themselves or by a legally acceptable representative. Initiation of corticosteroid pulse therapy (defined as methylprednisolone ≥500 mg or equivalent) within 48 hours of hospital admission, with an attending physician’s judgement that subsequent maintenance corticosteroid therapy is required. Initiation of corticosteroid pulse therapy (defined as methylprednisolone ≥500 mg or equivalent) within 48 hours of hospital admission, with an attending physician’s judgement that subsequent maintenance corticosteroid therapy is required. Exclusion criteria Patients meeting any of the following criteria will be excluded: Worsening of respiratory condition primarily due to lung infection, pneumothorax, pulmonary embolism or left heart failure. Worsening of respiratory condition primarily due to lung infection, pneumothorax, pulmonary embolism or left heart failure. Coexisting active malignancy. Coexisting active malignancy. Receiving mechanical ventilation via endotracheal intubation. Receiving mechanical ventilation via endotracheal intubation. Pregnant or breastfeeding, or possibility of pregnancy. Pregnant or breastfeeding, or possibility of pregnancy. Currently on a waiting list for lung transplantation. Currently on a waiting list for lung transplantation. Concurrent participation in another interventional clinical trial (participation in observational studies is permissible). Concurrent participation in another interventional clinical trial (participation in observational studies is permissible). Known hypersensitivity to the study drug components (prednisolone). Known hypersensitivity to the study drug components (prednisolone). Positive test for COVID-19, influenza A or influenza B at screening. Positive test for COVID-19, influenza A or influenza B at screening. Concomitant fungal or mycobacterial infection requiring systemic treatment. Concomitant fungal or mycobacterial infection requiring systemic treatment. Receiving ≥10 mg/day of prednisolone (or equivalent) at the onset of AE-IPF. Receiving ≥10 mg/day of prednisolone (or equivalent) at the onset of AE-IPF. Receiving immunosuppressive agent at the onset of AE-IPF. Receiving immunosuppressive agent at the onset of AE-IPF. Worsening of respiratory status during corticosteroid pulse therapy. Worsening of respiratory status during corticosteroid pulse therapy. Judged ineligible for the trial by the attending physician for any other reason. Judged ineligible for the trial by the attending physician for any other reason. AE-IPF, acute exacerbation of idiopathic pulmonary fibrosis; ATS/ERS/JRS/ALAT, American Thoracic Society/European Respiratory Society/Japanese Respiratory Society/Latin American Thoracic Association; IPF, idiopathic pulmonary fibrosis. Interventions Eligible participants will be randomly assigned to receive prednisolone according to either an accelerated 6-week tapering schedule (rapid tapering group) or a conventional 12-week tapering schedule (standard tapering group). Both interventions will be initiated following corticosteroid pulse therapy for AE-IPF. The initial daily dose of oral prednisolone will be 1.0 mg/kg of actual body weight for both groups, starting the day after the completion of pulse therapy. The subsequent tapering schedule for each group is detailed in table 1. After completion of the protocol-specified treatment period as detailed in table 1, prednisolone therapy can be either modified (eg, further tapered or maintained) or discontinued at the discretion of the attending physician at each participating site (local clinical practice). However, if there is no deterioration, the steroid dose should not be increased. The initial dose of 1 mg/kg/day was selected as a pragmatic choice reflecting one commonly used regimen in AE-IPF and prior trial precedent, including a published randomised trial (EXAFIP)16 and an ongoing trial (EXAFIP2; NCT05674994), rather than as the single predominant standard of care. Table 1Dosing schedule for prednisolone tapering regimensEarly tapering groupStandard tapering groupDays 1–4 (1–6)1.0 mg/kg/day1.0 mg/kg/dayDays 5–7 (3–9)0.8 mg/kg/day1.0 mg/kg/dayDays 8–9 (6–11)0.8 mg/kg/day0.8 mg/kg/dayDays 10–14 (8–16)0.6 mg/kg/day0.8 mg/kg/dayDays 15–21 (12–24)0.4 mg/kg/day0.6 mg/kg/dayDays 22–28 (19–31)0.2 mg/kg/day0.5 mg/kg/dayDays 29–42 (26–45)0.1 mg/kg/day0.4 mg/kg/dayDays 43–56 (40–59)Local practice0.3 mg/kg/dayDays 57–70 (54–73)Local practice0.2 mg/kg/dayDays 71–84 (68–87)Local practice0.1 mg/kg/dayDays 84–90 (81–90)Local practiceLocal practiceSubsequent dosing after day 42 (early tapering group) and day 84 (standard tapering group) is at the discretion of the attending physician (local clinical practice). Dosing schedule for prednisolone tapering regimens Subsequent dosing after day 42 (early tapering group) and day 84 (standard tapering group) is at the discretion of the attending physician (local clinical practice). Administration and flexibility Prednisolone will be administered systemically (eg, orally, intravenously), with the specific route and method at the discretion of the attending physician. Treatment will be initiated in an inpatient setting but may be transitioned to an outpatient basis on clinical improvement. The protocol allows for a degree of flexibility in the administration of prednisolone to accommodate real-world clinical practice: Dosage: minor variations from the prescribed daily dose are permissible, within ±10% of the calculated dose or ±5 mg, whichever is larger. Duration: the duration of each tapering step may be adjusted within the specific day ranges indicated in parentheses for each step in table 1 (eg, to accommodate weekends or patient convenience). All treatment decisions, including adherence to the allocated tapering schedule and management after the protocol-defined treatment period, will be made by the attending physicians at each participating site. No specific intervention manual beyond this protocol is provided. Criteria for discontinuation of protocol-specified prednisolone therapy The criteria under which protocol-specified prednisolone therapy will be discontinued are detailed in online supplemental additional file 1. Subsequent treatment will be at the discretion of the attending physician. Adherence to intervention No specific strategies to improve adherence to the allocated prednisolone regimens beyond routine clinical care are planned, as the initial treatment phase is predominantly hospital-based under direct medical supervision. Adherence will be assessed based on medication administration records during hospitalisation and investigator assessment of compliance with the tapering schedule. Any application of the protocol-defined flexibility (eg, dose or duration adjustments) as well as any other deviations from the protocol-specified treatment will be documented, along with the reasons for each instance. Concomitant care The use of concomitant medications to prevent potential steroid-related adverse events is strongly recommended. Standard medical care is permitted unless explicitly prohibited. A detailed list of prohibited medications and therapies is provided in online supplemental additional file 1. Outcomes The primary outcome is all-cause mortality at 90 days. Secondary outcomes will assess survival, clinical status (including respiratory function, patient-reported and clinician-reported outcomes) and safety. A comprehensive list of all primary and secondary outcomes is provided in box 2. Primary and secondary outcomes Primary outcome The primary outcome is all-cause mortality at 90 days following the initiation of protocol-specified therapy. Key secondary outcomes Key secondary outcomes include: The proportion of patients lost to follow-up by day 90. The proportion of patients lost to follow-up by day 90. Protocol adherence (assessed for the overall 90-day period and until the time of respiratory worsening or death). Protocol adherence (assessed for the overall 90-day period and until the time of respiratory worsening or death). All-cause mortality at 28 days. All-cause mortality at 28 days. Mortality due to respiratory causes by day 90. Mortality due to respiratory causes by day 90. Time to worsening of respiratory status (a composite of death or protocol-defined respiratory worsening) by day 90. Time to worsening of respiratory status (a composite of death or protocol-defined respiratory worsening) by day 90. Other secondary outcomes Other secondary outcomes include: All-cause mortality at 1 year. All-cause mortality at 1 year. Duration of the initial hospitalisation for AE-IPF. Duration of the initial hospitalisation for AE-IPF. Dyspnoea severity at day 90, assessed using the mMRC dyspnoea scale and the modified Borg scale. Dyspnoea severity at day 90, assessed using the mMRC dyspnoea scale and the modified Borg scale. ADL at day 90, assessed using the Barthel Index. ADL at day 90, assessed using the Barthel Index. Health-related quality of life at day 90, assessed using the EQ-5D-5L. Health-related quality of life at day 90, assessed using the EQ-5D-5L. Clinical Frailty Scale score at day 90. Clinical Frailty Scale score at day 90. Pulmonary function tests (FVC and DLCO) at day 90. Pulmonary function tests (FVC and DLCO) at day 90. Total cumulative dose of prednisolone received by participants over 90 days (including protocol-specified and any subsequent local practice administration within this period). Total cumulative dose of prednisolone received by participants over 90 days (including protocol-specified and any subsequent local practice administration within this period). Incidence of delirium during the 90-day period. Incidence of delirium during the 90-day period. Incidence of SAEs during the 90-day period. Incidence of SAEs during the 90-day period. Incidence of pre-specified steroid-related adverse events during the 90-day period. Incidence of pre-specified steroid-related adverse events during the 90-day period. ADL, activities of daily living; AE-IPF, acute exacerbation of idiopathic pulmonary fibrosis; DLCO, diffusing capacity of the lung for carbon monoxide; EQ-5D-5L, EuroQol 5-Dimension 5-Level questionnaire; FVC, forced vital capacity; mMRC, modified Medical Research Council; SAE, serious adverse event. Definition of disease worsening For the purposes of this trial, disease worsening is defined as either an increase in oxygen requirement at rest or an increase in the dose or prolongation of corticosteroid therapy due to investigator-judged relapse of AE-IPF. The detailed prespecified criteria are provided in online supplemental additional file 1. Harms: adverse event definition and assessment Adverse events and SAEs will be recorded from the time of informed consent until 90 days after treatment initiation. The detailed procedures for the definition, collection, assessment, grading, and reporting of harms are described in online supplemental additional file 1. Safety reporting All SAEs must be reported promptly by the site investigator to the principal investigator/study secretariat for their awareness. However, deaths considered by the investigator to be clearly attributable to the natural progression of AE-IPF will be recorded directly in the electronic Case Report Form (eCRF) as an outcome but will not be reported through the SAE reporting pathway. For deaths not attributable to AE-IPF or of unknown cause, the event leading to death will be reported as an SAE. The principal investigator will be responsible for reporting all other SAEs to the head of each research institution and the respective institutional review boards in accordance with institutional procedures and the applicable ethical guidelines. Participant timeline The schedule of enrolment, interventions, assessments and visits for participants is presented in table 2. This diagram details all study procedures and their timing from screening through the end of the follow-up period. Table 2Schedule of enrolment, interventions and assessmentsTimepoint →Screening/baselineDay 15 (±2 days)Day 28 (±7 days)Day 60 (±7 days)Day 90 (±7 days)Day 365Unscheduled (within day 90): treatment discontinuationUnscheduled (within day 90): respiratory worseningEnrolment Eligibility screening and informed consentXRandomisationXInterventions Early tapering group→(continues)(continues)(ends at Day 42)(Local practice) Standard tapering group→(continues)(continues)(continues)(ends at Day 84)Assessments Demographics and medical historyX Oxygen requirement at rest, SpO2XXXXXXXImaging Chest X-rayXXXXX Chest CT (HRCT)XXLaboratory Tests CBCXXXXX Liver/renal function (AST, ALT, Cre, etc)XXXXX Inflammatory markers (CRP, LDH)XXXXX KL-6, SP-DXX Arterial blood gas (PaO2/FiO2)X Influenza/COVID-19 Test (PCR or Antigen)XPulmonary function tests (PFTs) FVC, DLCOX*XPatient-reported and clinician-reported outcomes mMRC, Modified Borg ScaleXX Barthel IndexXX EQ-5D-5LXX Clinical Frailty ScaleXXSafety assessments Adverse events, deliriumXXXXX SAEsXXXXXOther assessments Discontinuation assessmentX Worsening assessmentX Survival statusXXXXXXXAdditional laboratory or imaging tests may be performed at the investigator’s discretion at the time of discontinuation or worsening.*For PFTs, results from tests performed within 180 days prior to enrolment will be used. No new PFTs will be performed for study purposes between the onset of AE-IPF and enrolment.†Discontinuation assessment includes collection of data on the date and reason for discontinuation, respiratory support methods and overall clinical status (improved/worsened).‡Worsening assessment includes collection of data on the date of worsening, the specific protocol-defined criteria for worsening that were met, and the suspected cause of worsening (eg, AE-IPF relapse, pneumonia).CBC, complete blood count; Cre, creatinine; CRP, C reactive protein; DLCO, diffusing capacity of the lung for carbon monoxide; EQ-5D-5L, EuroQol 5-Dimension 5-Level questionnaire; FVC, forced vital capacity; HRCT, high-resolution CT; KL-6, Krebs von den Lungen-6; LDH, lactate dehydrogenase; mMRC, modified Medical Research Council; PaO2/FiO2, ratio of arterial oxygen partial pressure to fractional inspired oxygen; PFTs, pulmonary function tests; SAE, serious adverse event; SP-D, surfactant protein D. Schedule of enrolment, interventions and assessments Additional laboratory or imaging tests may be performed at the investigator’s discretion at the time of discontinuation or worsening. For PFTs, results from tests performed within 180 days prior to enrolment will be used. No new PFTs will be performed for study purposes between the onset of AE-IPF and enrolment. Discontinuation assessment includes collection of data on the date and reason for discontinuation, respiratory support methods and overall clinical status (improved/worsened). Worsening assessment includes collection of data on the date of worsening, the specific protocol-defined criteria for worsening that were met, and the suspected cause of worsening (eg, AE-IPF relapse, pneumonia). CBC, complete blood count; Cre, creatinine; CRP, C reactive protein; DLCO, diffusing capacity of the lung for carbon monoxide; EQ-5D-5L, EuroQol 5-Dimension 5-Level questionnaire; FVC, forced vital capacity; HRCT, high-resolution CT; KL-6, Krebs von den Lungen-6; LDH, lactate dehydrogenase; mMRC, modified Medical Research Council; PaO2/FiO2, ratio of arterial oxygen partial pressure to fractional inspired oxygen; PFTs, pulmonary function tests; SAE, serious adverse event; SP-D, surfactant protein D. Sample size calculation The required sample size was calculated for the primary outcome of 90-day all-cause mortality. Based on a non-inferiority design with 80% power, a one-sided significance level of 0.2 and a 10% risk difference margin, a total of 64 participants (32 per group) are required. To account for potential dropouts or exclusions from the analysis, the target enrolment is set at 70 participants (35 per group). The detailed assumptions and justifications for these parameters are provided in online supplemental additional file 1. Interim analyses The trial incorporates two planned interim analyses. First, an interim analysis for feasibility will be conducted after the first 30 participants have completed their 90-day follow-up. This analysis will assess the proportion of loss to follow-up and protocol adherence. The threshold of 20% for loss to follow-up is based on established evidence that losses exceeding this level pose serious threats to trial validity.17 The threshold of 70% for protocol adherence was determined based on the collective clinical expertise and judgement of the research group, in accordance with the general framework for feasibility progression criteria.18 19 If the proportion of loss to follow-up exceeds 20% or the proportion of protocol adherence is below 70%, the trial may be discontinued or the protocol may be revised. Second, an adaptive interim analysis for sample size re-estimation will be performed once 90-day primary outcome data are available for 60 participants. Following the method described by Uemura et al,20 the conditional power will be calculated based on the observed risk difference. If the conditional power is less than 20%, the trial will be considered for early termination due to futility or will continue to the initially planned sample size of 70. If the conditional power is less than 20%, the trial will be considered for early termination due to futility or will continue to the initially planned sample size of 70. If the conditional power is 20% or greater, the sample size will be recalculated based on the interim data and enrolment will continue up to the revised target. The maximum total sample size is capped at 130 participants. If the conditional power is 20% or greater, the sample size will be recalculated based on the interim data and enrolment will continue up to the revised target. The maximum total sample size is capped at 130 participants. The results of both interim analyses will be reviewed by the principal investigator and the study statistician. Recruitment To achieve the target sample size, potentially eligible patients will be identified by screening all individuals hospitalised for AE-IPF at the participating centres. Attending physicians or study staff at each site will approach identified patients or their legally acceptable representatives to provide study information and obtain informed consent. The primary strategy to ensure adequate and timely enrolment is the expansion of the trial network; additional collaborating hospitals will be invited to join if the recruitment rate is slower than anticipated. The study secretariat will regularly monitor enrolment progress to manage this process. Randomisation and blinding Participants will be randomly assigned in a 1:1 ratio to either the rapid or standard tapering group. Randomisation will be performed centrally at the JORTC Data Center using a computer-generated minimisation method. The allocation will be stratified by two factors: the use of anti-fibrotic medication (yes vs no) and long-term home oxygen therapy (yes vs no) at baseline. Site investigators will enrol participants and receive the treatment allocation via a secure, web-based system, ensuring allocation concealment. This is a fully open-label trial, and no personnel, including participants, investigators, outcome assessors or data analysts, will be blinded to treatment allocation. Data collection and management Data for all participants will be collected by site investigators or designated study staff and recorded in a centralised, secure, web-based eCRF system developed and maintained by the JORTC Data Center. The schedule of all assessments is detailed in table 2. While all required data can be entered manually, prespecified data such as laboratory results and medication records may also be extracted directly from the electronic health record systems of participating hospitals, where feasible, to supplement direct data entry and reduce administrative burden. In the event of discontinuation from the allocated intervention, participants will be encouraged to continue follow-up for key outcome assessments, particularly survival status, unless consent is fully withdrawn. Data management will be conducted by the JORTC Data Centre in accordance with applicable national ethical guidelines and the principles of Good Clinical Practice. A separate, detailed data management plan will be developed prior to the trial. The eCRF system will have built-in data validation checks (eg, range checks), and a query management process will be used to ensure data quality. Access to all trial data will be restricted to authorised personnel. Participant data will be de-identified using a unique study ID, and all data will be stored securely and encrypted at the data centre. Essential trial documents will be archived for a minimum of 10 years after publication. Statistical analysis All statistical analyses will be performed by the study statistician according to the prespecified SAP. The main principles of the analysis are outlined here. All efficacy analyses will be conducted on the intention-to-treat population, which includes all randomised participants, analysed in the group to which they were originally assigned, regardless of adherence to the intervention. To assess the impact of protocol deviations, an adherence-adjusted analysis using inverse probability weighting will be conducted as a sensitivity analysis, with details specified in the SAP. A safety population, consisting of all participants who received at least one dose of prednisolone, will be used for the analysis of safety data. Primary outcome analysis The primary outcome, 90-day all-cause mortality, will be compared between the two groups. The proportion of deceased patients and its 95% CI in each group will be calculated using the Kaplan-Meier method, with the CI estimated using Greenwood’s formula. To test for non-inferiority, the risk difference between the groups will be assessed using a Wald test with a prespecified non-inferiority margin of 10 percentage points (0.1) and a one-sided significance level of 0.2. Secondary outcome analyses All secondary outcomes will be analysed on an exploratory basis to estimate treatment effects, without a formal hypothesis testing for statistical significance. Key secondary outcome analyses The following methods will be used to describe and compare the key secondary outcomes: For 28-day all-cause mortality, the proportion of deceased patients in each group will be estimated using the Kaplan-Meier method, and the risk difference with its 95% CI will be calculated. For 28-day all-cause mortality, the proportion of deceased patients in each group will be estimated using the Kaplan-Meier method, and the risk difference with its 95% CI will be calculated. For mortality due to respiratory causes, where death from other causes is a competing risk, cumulative incidence functions will be estimated for each group. For mortality due to respiratory causes, where death from other causes is a competing risk, cumulative incidence functions will be estimated for each group. For the composite outcome of time to respiratory worsening or death, Kaplan-Meier curves will be generated for each group. A Cox proportional hazards model will be used to estimate the HR and its 95% CI. For the composite outcome of time to respiratory worsening or death, Kaplan-Meier curves will be generated for each group. A Cox proportional hazards model will be used to estimate the HR and its 95% CI. Protocol adherence will be assessed in two ways:Adherence up to the point of respiratory worsening or death: This will be summarised descriptively.Overall adherence during the entire 90-day treatment period: This will be presented as a proportion with a 95% CI for each group, with reasons for non-adherence also summarised. Protocol adherence will be assessed in two ways: Adherence up to the point of respiratory worsening or death: This will be summarised descriptively. Adherence up to the point of respiratory worsening or death: This will be summarised descriptively. Overall adherence during the entire 90-day treatment period: This will be presented as a proportion with a 95% CI for each group, with reasons for non-adherence also summarised. Overall adherence during the entire 90-day treatment period: This will be presented as a proportion with a 95% CI for each group, with reasons for non-adherence also summarised. The proportion of patients lost to follow-up will be presented as proportions with 95% CIs for each group. The proportion of patients lost to follow-up will be presented as proportions with 95% CIs for each group. Other secondary outcome analyses The statistical methods for other secondary outcomes, including 1-year all-cause mortality, continuous outcomes at day 90 (dyspnoea, activities of daily living, quality of life, pulmonary function), hospitalisation duration, cumulative steroid dose and adverse events, are detailed in online supplemental additional file 1. Handling of missing data For the primary outcome and other time-to-event secondary outcomes, minimal missing data are anticipated and analyses will be based on all available data without imputation. For continuous secondary outcomes, the general principles and detailed rules for handling missing data will be prespecified in the SAP and are described in online supplemental additional file 1. Sensitivity analyses will be performed to assess the impact of the findings under different assumptions about the missing data mechanism. Use of artificial intelligence During the preparation of this manuscript, the authors used the large language model Gemini 3.1 Pro and Claude Sonnet 4.6 to improve readability and assist with proofreading the English text. After using these tools, the authors reviewed and edited the content as needed and took full responsibility for the final content of the publication. Monitoring An independent Data Monitoring Committee (DMC) will not be established for this trial. A DMC was considered unnecessary given that (1) the trial investigates different tapering strategies of a widely used medication (prednisolone) rather than a novel investigational product, (2) the trial has an open-label design, allowing for continuous safety monitoring by site investigators and (3) the primary outcome is short-term (90 days). Trial monitoring will be conducted centrally by the JORTC Data Center following a prespecified monitoring plan. Any significant safety signals or data integrity issues identified will be communicated promptly to the principal investigator and the study statistician for review and action. No on-site monitoring or independent auditing is planned for this trial. The principal investigator reserves the right to terminate the trial at any time due to safety concerns, significant recruitment difficulties or compelling external evidence. Patient and public involvement Patients and public participants were not involved in the design, conduct, reporting or dissemination plans of this research. This was an investigator-initiated trial focused on a specific clinical question regarding treatment strategy, and formal mechanisms for patient and public involvement were not in place at the time of study design. Future trials should consider incorporating patient perspectives in the study design. Discussion The RAPID-IPF trial is the first prospective RCT designed to investigate the optimal tapering strategy for corticosteroids in patients with AE-IPF. Given the exploratory nature of this trial, the findings should be regarded as preliminary evidence. If the hypothesis of non-inferiority for the rapid (6 weeks) tapering regimen is confirmed, the results would provide important preliminary evidence to inform clinical practice and to support the design of future confirmatory trials, potentially enabling a shorter treatment duration with reduced cumulative corticosteroid exposure, without compromising survival. This would represent a meaningful step towards establishing a safer and more patient-centred management approach for this devastating condition. A recent systematic review reported inconsistent findings regarding corticosteroid use in AE-IPF, with some observational studies suggesting a possible association between higher doses and increased mortality.21 However, this evidence is subject to substantial confounding by indication, as more severely ill patients are more likely to receive higher doses. The review itself concluded that randomised evidence is needed, and the RAPID-IPF trial contributes to this effort. Strength and limitation This trial has several strengths. The randomised, controlled design minimises selection bias and confounding inherent in previous observational studies. The multicentre approach enhances generalisability. Furthermore, the adaptive sample size re-estimation ensures adequate power despite uncertainty in the treatment effect. However, we acknowledge several potential limitations. First, the open-label design may introduce bias. Its impact on mortality is likely minimal; however, subjective secondary outcomes—such as the decision to escalate corticosteroid therapy, dyspnoea scales and the Clinical Frailty Scale—may be more susceptible. Predefined criteria for disease worsening are specified to minimise subjectivity, but this potential for bias should be acknowledged. Second, a key methodological consideration is the choice of a one-sided significance level of 0.2 for the primary non-inferiority analysis. Given the complete absence of randomised evidence for corticosteroid tapering strategies in AE-IPF, this trial is more appropriately characterised as a phase II-type randomised trial aimed at generating preliminary evidence to inform future confirmatory research. The use of a one-sided α of 0.2 is consistent with recommendations for such exploratory designs.22 23 Nevertheless, this threshold increases the risk of a type I error. Furthermore, the combination of these design features—a permissive α, a 10% non-inferiority margin, adaptive sample size re-estimation, open-label design and absence of a DMC—may increase the risk of falsely reassuring conclusions, particularly given the small sample size. Accordingly, if non-inferiority is demonstrated, a finding should be interpreted as preliminary evidence to guide clinical practice and to inform the design of future confirmatory trials, rather than as definitive proof of non-inferiority. Third, recruitment is restricted to tertiary care centres in Japan, which may limit generalisability. Corticosteroid tapering practices, patient demographics and supportive care standards may differ internationally, and the 12-week comparator regimen may not represent approaches used in other regions. Fourth, missing data for certain secondary outcomes is anticipated, and our statistical approach, including the use of trimmed means, is designed to mitigate its impact, though interpretation will require care. Additionally, this trial was designed without formal patient and public involvement (PPI). Patient engagement in trial design is increasingly recognised as important for ensuring that research questions, outcome measures and trial procedures reflect the priorities and experiences of those most affected. The absence of PPI may have limited the patient-centredness of the trial design, including outcome selection and procedural acceptability. Finally, this trial is designed to compare two corticosteroid tapering strategies and does not address the broader question of whether corticosteroid tapering confers any benefit over no corticosteroid treatment following pulse therapy. This question would require a separate RCT with an appropriate comparator arm to address. More broadly, the efficacy of corticosteroids in AE-IPF itself remains unproven, and a placebo-controlled trial would represent the most rigorous approach to evaluating this question. However, recruitment to such a trial may be particularly challenging in AE-IPF. Corticosteroid use has become standard practice at many centres, and clinicians and patients confronted with this life-threatening condition may be reluctant to participate in a placebo-controlled trial.24 An ongoing placebo-controlled trial (EXAFIP2; NCT05674994) may help address this question. Conclusion The RAPID-IPF trial is designed to generate preliminary prospective evidence on the optimal corticosteroid tapering strategy for patients with AE-IPF and to inform the design of future confirmatory studies. Confidentiality All personal participant data will be kept confidential and protected in accordance with applicable data protection regulations. Data will be de-identified using a unique participant ID for all analyses and reports. Access to identifiable data will be restricted to authorised personnel at the participating sites. Ancillary and post-trial care Participants will receive all standard clinical care required for their condition during and after the trial. Compensation for significant harm arising from trial participation will be provided through a clinical research insurance policy. Supplementary material Acknowledgements The authors would like to thank the clinical research coordinators and staff at all participating sites for their valuable contributions to the planning and preparation of this trial. Footnotes Funding: This study is funded in part by JSPS KAKENHI [grant number 24K19108] and Japan Research Foundation for Clinical Pharmacology. There are no other sources of funding at this time. This work is also supported by institutional resources from Kyoto University. The funder has no role in the study design; collection, management, analysis and interpretation of data; writing of the report; or the decision to submit the report for publication. Provenance and peer review: Not commissioned; externally peer reviewed. Patient consent for publication: Not applicable. Patient and public involvement: Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research. Ethics approval: This study will be conducted in compliance with the principles of the Declaration of Helsinki and relevant Japanese ethical guidelines. The protocol was approved by the IRB of each participating site, led by the IRB of Saiseikai Kumamoto Hospital (approval no: 1367). Any substantial amendments will require further IRB approval before implementation. Written informed consent will be obtained from all participants or their legally acceptable representatives before any trial-specific procedures are performed. Results will be disseminated through peer-reviewed publication and the trial registry, regardless of outcome. Data availability statement Data sharing is not applicable as no datasets were generated and/or analysed for this study. References Associated Data Supplementary Materials Data Availability Statement Data sharing is not applicable as no datasets were generated and/or analysed for this study.